AKT1 and leukemia: To determine whether the PI3K/Akt pathway is involved in drug resistance through the regulation of ABCG2, leukemia cells were treated with the PI3K inhibitor LY294002 (20 μM) or the mTOR inhibitor rapamycin (100 nM) for 72 h.